Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of auto-antibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy are topical and systemic corticosteroids (CS) and immunosuppressors. As this pathology mainly involves the elderly, subjects often have numerous comorbidities that influence the clinical management. Omalizumab is a recombinant humanized monoclonal anti-IgE antibody which has recently emerged as a promising treatment for BP in patients for whom CS are contraindicated or conventional treatments have failed to control the disease.
Browse by Audience
Skip to content